AstraZeneca

AstraZeneca CEO reassures staff, aims to be at September cancer meet
AstraZeneca CEO reassures staff, aims to be at September cancer meet
Reuters
AstraZeneca
Pharma CEOs
Pascal Soriot
Teva Pharmaceutical
Flag link:
5 Big Pharma Stocks With the Best Drug Pipelines
5 Big Pharma Stocks With the Best Drug Pipelines
Motley Fool
Big Pharma
Roche
AstraZeneca
AbbVie
Gilead Sciences
JNJ
Flag link:
Will he stay or will he go? AZ's shares jump, Teva's sink on report that Soriot will stay put
Will he stay or will he go? AZ's shares jump, Teva's sink on report that Soriot will stay put
Fierce Pharma
AstraZeneca
Pascal Soriot
Teva Pharmaceutical
Pharma CEOs
Flag link:
Cancer-fighting PARP drugs from AstraZeneca, Clovis and Tesaro largely overpriced, watchdog says
Cancer-fighting PARP drugs from AstraZeneca, Clovis and Tesaro largely overpriced, watchdog says
Fierce Pharma
PARP inhibitors
AstraZeneca
Clovis Oncology
Tesaro
drug pricing
Flag link:
Soriot skipping over to Teva ahead of MYSTIC results?
Soriot skipping over to Teva ahead of MYSTIC results?
BioPharma Dive
Pascal Soriot
AstraZeneca
Pharma CEOs
Teva Pharmaceutical
tremelimumab
Flag link:
Terrible optics: AstraZeneca shares take a hit following report that CEO Soriot is moving to Teva
Terrible optics: AstraZeneca shares take a hit following report that CEO Soriot is moving to Teva
Endpoints
AstraZeneca
Pascal Soriot
Pharma CEOs
Teva Pharmaceutical
Flag link:
AstraZeneca's CEO Soriot to join Israeli drugs company Teva: report
AstraZeneca's CEO Soriot to join Israeli drugs company Teva: report
Reuters
AstraZeneca
Pascal Soriot
Pharma CEOs
Teva Pharmaceutical
Flag link:
AstraZeneca Expects Brilinta to Become a Blockbuster Therapy in 2017
AstraZeneca Expects Brilinta to Become a Blockbuster Therapy in 2017
Market Realist
AstraZeneca
Brilinta
Flag link:
What the FDA's Hold on Three Merck Studies Means for Other Drug Makers
What the FDA's Hold on Three Merck Studies Means for Other Drug Makers
TheStreet.com
Merck
Keytruda
FDA
clinical trials
Multiple Myeloma
Bristol-Myers Squibb
AstraZeneca
Celgene
Flag link:
Ex-AstraZeneca executive Luke Miels accuses CEO Soriot of threatening him for taking GSK job
Ex-AstraZeneca executive Luke Miels accuses CEO Soriot of threatening him for taking GSK job
Fierce Pharma
Pascal Soriot
Pharma CEOs
Luke Miels
GSK
AstraZeneca
Flag link:
AstraZeneca Expected to Report Fall in Revenues in 2017
AstraZeneca Expected to Report Fall in Revenues in 2017
Market Realist
AstraZeneca
earnings
Flag link:
Investors — and AstraZeneca CEO Pascal Soriot — are getting a tad nervous as MYSTIC data loom
Investors — and AstraZeneca CEO Pascal Soriot — are getting a tad nervous as MYSTIC data loom
Endpoints
investors
AstraZeneca
Pascal Soriot
Imfinzi
tremelimumab
immuno-oncology
clinical trials
Flag link:
AstraZeneca's struggling FluMist loses out on crucial CDC vaccine backing—again
AstraZeneca's struggling FluMist loses out on crucial CDC vaccine backing—again
Fierce Pharma
AstraZeneca
FluMist
CDC
vaccines
Flag link:
Pfizer Fueling Growth Of Competitors' Pipelines
Pfizer Fueling Growth Of Competitors' Pipelines
Forbes
Pfizer
R&D
Clovis Oncology
Puma Biotechnology
Bioventus
Shire
AstraZeneca
Flag link:
AstraZeneca at Cannes: Healthcare delivery's speeding away from pharma's marketing model
AstraZeneca at Cannes: Healthcare delivery's speeding away from pharma's marketing model
Fierce Pharma
AstraZeneca
pharma marketing
Flag link:
For AstraZeneca, Cancer Drug Weighs on Go-It-Alone Stand
For AstraZeneca, Cancer Drug Weighs on Go-It-Alone Stand
FOX Business
AstraZeneca
Mystic
lung cancer
Flag link:
GSK's new pharma head to join in September after AstraZeneca tussle
GSK's new pharma head to join in September after AstraZeneca tussle
Yahoo/Reuters
GSK
AstraZeneca
Luke Miels
Flag link:
New test may turn AZ's Lynparza into precision drug for prostate cancer
New test may turn AZ's Lynparza into precision drug for prostate cancer
Yahoo/Reuters
AstraZeneca
Lynparza
prostate cancer
Flag link:
Can AstraZeneca Keep Up As Clovis, Tesaro Unveil Blockbuster Drugs?
Can AstraZeneca Keep Up As Clovis, Tesaro Unveil Blockbuster Drugs?
Investors Business Daily
AstraZeneca
Clovis
Tesaro
PARP inhibitors
Flag link:
AstraZeneca, Boehringer cry 'no class effect' after Johnson & Johnson's Invokana doubles amputations in study
AstraZeneca, Boehringer cry 'no class effect' after Johnson & Johnson's Invokana doubles amputations in study
Fierce Pharma
AstraZeneca
Boehringer Ingelheim
JNJ
Invokana
diabetes
Jardiance
amputation
Flag link: